HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Passive Monitoring of Short-Acting Beta-Agonist Use via Digital Platform in Patients With Chronic Obstructive Pulmonary Disease: Quality Improvement Retrospective Analysis.

AbstractBACKGROUND:
Digital health programs assist patients with chronic obstructive pulmonary disease (COPD) to better manage their disease. Technological and adoption barriers have been perceived as a limitation.
OBJECTIVE:
The aim of the research was to evaluate a digital quality improvement pilot in Medicare-eligible patients with COPD.
METHODS:
COPD patients were enrolled in a digital platform to help manage their medications and symptoms as part of their routine clinical care. Patients were provided with electronic medication monitors (EMMs) to monitor short-acting beta-agonist (SABA) use passively and a smartphone app to track use trends and receive feedback. Providers also had access to data collected via a secure website and were sent email notifications if a patient had a significant change in their prescribed inhaler use. Providers then determined if follow-up was needed. Change in SABA use and feasibility outcomes were evaluated at 3, 6, and 12 months.
RESULTS:
A total of 190 patients enrolled in the pilot. At 3, 6, and 12 months, patients recorded significant reductions in daily and nighttime SABA use and increases in SABA-free days (all P<.001). Patient engagement, as measured by the ratio of daily active use to monthly active use, was >90% at both 6 and 12 months. Retention at 6 months was 81% (154/190). Providers were sent on average two email notifications per patient during the 12-month program.
CONCLUSIONS:
A digital health program integrated as part of standard clinical practice was feasible and had low provider burden. The pilot demonstrated significant reduction in SABA use and increased SABA-free days among Medicare-eligible COPD patients. Further, patients readily adopted the digital platform and demonstrated strong engagement and retention rates at 6 and 12 months.
AuthorsJessica Chen, Leanne Kaye, Michael Tuffli, Meredith A Barrett, Shelanda Jones-Ford, Tina Shenouda, Rahul Gondalia, Kelly Henderson, Veronica Combs, David Van Sickle, David A Stempel
JournalJMIR formative research (JMIR Form Res) Vol. 3 Issue 4 Pg. e13286 (Oct 23 2019) ISSN: 2561-326X [Electronic] Canada
PMID31647471 (Publication Type: Journal Article)
Copyright©Jessica Chen, Leanne Kaye, Michael Tuffli, Meredith A Barrett, Shelanda Jones-Ford, Tina Shenouda, Rahul Gondalia, Kelly Henderson, Veronica Combs, David Van Sickle, David A Stempel. Originally published in JMIR Formative Research (http://formative.jmir.org), 23.10.2019.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: